AQS.V - Aequus Pharmaceuticals Inc.
| Previous Close | 0.27 |
| Open | 0.26 |
| Bid | 0.25 x 0 |
| Ask | 0.26 x 0 |
| Day's Range | 0.25 - 0.27 |
| 52 Week Range | 0.14 - 0.45 |
| Volume | 161,000 |
| Avg. Volume | 209,242 |
| Market Cap | 18.103M |
| Beta | -0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.07 |
| Earnings Date | Apr 30, 2018 - May 4, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.52 |
- GlobeNewswire•2 days ago
Aequus and Camargo Complete Pre-Investigational New Drug Submission with FDA for Transdermal Anti-Nausea Program
VANCOUVER, British Columbia, April 17, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today ...
- Baystreet•6 days ago
Big Pharma says It Must Collaborate with Juniors to Revive Real Innovation
Innovation in the pharmaceutical industry has come a long way in the last few decades, but with the ...
- GlobeNewswire•7 days ago
Aequus Adds Zepto Capsulotomy System, A Revenue Generating Product, to Commercial Ophthalmology Portfolio
VANCOUVER, B.C., April 12, 2018-- Aequus Pharmaceuticals Inc., is pleased to announce it has entered into a commercial agreement with Mynosys Cellular Devices, an ophthalmology focused medical device company ...
- GlobeNewswire•last month
Aequus Expands Market in Quebec for Tacrolimus IR
VANCOUVER, British Columbia, March 19, 2018-- Aequus Pharmaceuticals Inc., announced today that it has been awarded a three-year contract with Sigma Santé for its partnered product, tacrolimus immediate-release, ...
- Baystreet•last month
Drug Makers Use Nanotechnology to Improve Delivery and Dosing
In order to advance the delivery of specialized medicines and dosage, scientists are looking to improvements ...
- GlobeNewswire•last month
FDA Confirms Date to Providing Regulatory Guidance for Aequus’ Anti-Nausea Patch
VANCOUVER, British Columbia, March 07, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today ...
- PR Newswire•last month
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.
- CNW Group•last month
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
VANCOUVER, March 5, 2018 /CNW/ - Aequus Pharmaceuticals Inc. (TSX-V:AQS.V - News) (OTCQB:AQSZF - News) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (OTCQB:EHVVF - News) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.
- PR Newswire•last month
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc. (EHVVF) ("Ehave"), a healthcare bioinformatics company whose platform efficiently captures, integrates, and delivers high-quality clinical data and treatment tools, have entered into a collaboration agreement whereby Aequus will incorporate Ehave's bioinformatics platform to enhance and streamline data management processes for Aequus-sponsored clinical trials studying specific Cannabinoid-rich formulations for treating a number of neurological disorders. The Companies had been working together under a previously announced Letter of Intent established in August 2017.
- GlobeNewswire•last month
Aequus and Ehave Enter Into Collaboration Agreement for Comprehensive Patient Data Management in Clinical Trials of Medical Cannabis
VANCOUVER, British Columbia, March 05, 2018-- Aequus Pharmaceuticals Inc., a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, and Ehave, Inc., ...
- Baystreet•2 months ago
New Drug Delivery Technologies Extending to Even Aspirin
Missed drug dosses are not only risky to concerned patients, but to the global healthcare system as ...
- Marketwired•3 months ago
Aequus Announces Closing of $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...
- Marketwired•3 months ago
Aequus and Camargo Prepare for Meeting with FDA to Advance Anti-Nausea Patch
Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced plans to advance its...
- Marketwired•3 months ago
Aequus Announces Change to Proposed $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...
- Marketwired•3 months ago
Aequus Announces Proposed $300,000 Equity Financing
NOT FOR DISTRIBUTION OR DISSEMINATION INTO THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICESAequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing,...
- PR Newswire•3 months ago
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders
OTTAWA, Jan. 11, 2018 /PRNewswire/ - CannaRoyalty Corp. (CSE:CRZ) (CNNRF) ("CannaRoyalty") and Aequus Pharmaceuticals Inc. (AQS.V) (AQSZF) ("Aequus") (together the "Partners"), today announced a collaboration (the "JV") to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by clinical data focused on the medical community.
- CNW Group•3 months ago
CannaRoyalty and Aequus Pharmaceuticals Announce Joint Venture to Develop and Commercialize Cannabis-Based Therapies Targeting Neurological Disorders
OTTAWA, Jan. 11, 2018 /CNW/ - CannaRoyalty Corp. (CSE:CRZ) (OTCQX:CNNRF - News) ("CannaRoyalty") and Aequus Pharmaceuticals Inc. (TSX-V:AQS.V - News) (OTCQB:AQSZF - News) ("Aequus") (together the "Partners"), today announced a collaboration (the "JV") to advance a suite of cannabis-based therapies targeting neurological disorders into clinical trials in Canada, in collaboration with Canadian doctors and key opinion leaders. CannaRoyalty and Aequus have formed this collaboration to clinically advance a number of cannabis-based therapies in partnership with Canadian clinicians to create truly differentiated products supported by clinical data focused on the medical community.
- Marketwired•4 months ago
Aequus announces the issuance of stock options
Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options...
- Marketwired•5 months ago
Aequus Provides Third Quarter 2017 Operational Highlights
Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today reported financial results for the three...
- Marketwired•5 months ago
Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole
Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent...
- Marketwired•6 months ago
Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole
Aequus Pharmaceuticals Inc. , a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the State Intellectual...
- Baystreet•8 months ago
Stocks in play: Aequus Pharmaceuticals Inc.
Has received a receipt for its final short form base shelf prospectus. The Prospectus will allow Aequus ...